Top Page
IXICO plc
(LSE:IXI)
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
IXICO plc Business Overview & Revenue Model
IXICO plc Earnings Call Summary
IXICO plc Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.53M | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 3.09M | 2.77M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.07M | -2.02M | -1.95M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.65M | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | ||||||
| Total Assets | 13.84M | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.54M | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 179.00K | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.10M | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 11.74M | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | ||||||
| Free Cash Flow | -979.00K | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -928.00K | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -870.00K | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | 3.50M | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Technical Analysis
IXICO plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £42.94M | 7.77 | ― | 2.94% | 11.92% | -33.76% | |
58 Neutral | £10.89M | -6.32 | -15.57% | ― | 13.32% | 55.07% | |
52 Neutral | £26.97M | -6.96 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £864.14K | -1.58 | -85.21% | ― | 44.32% | 60.00% | |
42 Neutral | £267.00M | ― | ― | ― | ― | ― | |
38 Underperform | £10.08M | -0.26 | -407.49% | ― | 72.17% | 79.03% |
IXICO plc Corporate Events
IXICO plc has announced the issuance of 1,400,000 share options to its broader leadership team, with vesting criteria tied to retention and annual revenue growth over three years. This strategic move aims to align leadership incentives with company growth objectives, potentially strengthening IXICO’s market position in the neuroscience precision medicine sector.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc reported a strong financial performance for the year ended 30 September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss. The company’s strategic focus on innovation, leadership, and scaling has resulted in significant commercial traction, evidenced by a 27% increase in its order book since the year-end. The company continues to expand its AI-powered platform into new industry verticals and has secured substantial contracts in Alzheimer’s and Huntington’s disease research, positioning itself for further growth in the neuroscience sector.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc reported strong financial results for the year ending September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss, driven by its Innovate Lead Scale strategy. The company achieved significant growth in its order book and expanded its operations in North America, while also diversifying revenue streams and enhancing its AI-powered platform. These advancements position IXICO to continue its leadership in neuroimaging and biomarker analytics, benefiting stakeholders by accelerating drug development for neurological disorders.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc has announced the appointment of two renowned experts in Alzheimer’s Disease and cerebrovascular disease to its Scientific Advisory Board, strengthening its focus on dementia research and product innovation, particularly in vascular biomarkers. This strategic move, unveiled at the 2025 CTAD Conference, aims to enhance IXICO’s capabilities in developing biomarker algorithms to improve clinical trial design and efficacy interpretation, thereby reinforcing its position in the neurological research community.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc has announced it will release its Full Year Results for the year ending 30 September 2025 on 09 December 2025. The company’s CEO, Bram Goorden, and CFO, Grant Nash, will present the results and discuss the company’s progress and strategy in a live presentation open to shareholders. This announcement is significant as it provides stakeholders with insights into IXICO’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc has secured a significant contract worth over £3.5 million to provide imaging services for a global Phase 3 clinical trial in Huntington’s Disease (HD). This contract underscores IXICO’s expertise in HD and its strategic growth in the neuroscience precision medicine field. The deal is part of IXICO’s ‘Innovate, Lead, Scale’ strategy, which aims to drive global expansion and growth. The company’s involvement in this trial highlights its role in the HD research ecosystem and its commitment to advancing treatments for this rare neurodegenerative disorder.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc announced the availability of a recording from its Capital Markets Day, highlighting its strategic focus on AI-driven platform innovation and partnerships with biopharma and AI leaders in neurological precision medicine. The company aims to continue its double-digit topline growth and achieve medium-term profitability, emphasizing the importance of evolving its technology to maintain its market position.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc announced a trading update for the financial year ended September 30, 2025, reporting a 13% increase in revenues to £6.5 million, exceeding market expectations. The company secured new contracts and extended existing ones, contributing to a year-end order book of £13.8 million. With a year-end cash position of £3.5 million, IXICO also completed a capital raise, enabling investments in growth areas. The company anticipates a slightly improved EBITDA loss of no more than £1.6 million, reflecting strategic investments aimed at sustaining growth. CEO Bram Goorden expressed optimism about continued growth and value creation in the neurodegenerative disease biopharma R&D market.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc announced a new commercial contract and a contract extension worth a combined £1.2 million, strengthening its position in the blood-based biomarker field and Alzheimer’s Disease clinical trials. This development is part of IXICO’s ‘Innovate, Lead, Scale’ strategy, reflecting the company’s growing demand and expertise in the field, and enhancing its long-term order book with major biopharma clients.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
IXICO plc announced it will host a Capital Markets Day on 30 October 2025, offering insights into its growth strategy, technology roadmap, and future direction in the neuroscience field. The event will feature presentations from IXICO’s senior management, key customers, and industry leaders, highlighting the company’s AI-driven precision medicine technology platform and expansion opportunities. Existing and prospective investors can join via a live webcast, with the opportunity to engage with the company through a Q&A session.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.